Prof. Charles Emmanuel Jebaraj. W is a Cancer Biologist with over 23 years of experience in Molecular Oncology and Cancer Immunology. After completing his postgraduate studies in Biochemistry, he began interdisciplinary research in Biotechnology and Cancer Biology, developing yolk antibodies against mucin glycoproteins for cancer diagnostics. In 2001, he joined Sri Ramachandra Institute of Higher Education and Research (SRIHER), where he has significantly advanced cancer research. In 2010, Prof. Charles, was awarded the ICMR Young Biomedical Scientist “International Fellowship”, allowing him to pursue research at Stanford University under the mentorship of Prof. Jayakumar Rajadas and Prof. Geoffrey C. Gurtner.
He currently serves as Professor of Biotechnology at SRIHER, and leads the Molecular Oncology Laboratory, where six PhD Scholars are actively conducting research. His contributions include high-impact publications in journals such as BBA Molecular basis of disease, Metabolic Brain Disease, PeerJ, Life Sciences, Expert Reviews in Molecular Diagnostics with notable citations in Nature. His research focuses on developing diagnostic tools and therapeutic strategies for ovarian, gastrointestinal, colorectal, urogenital and brain malignancies. He currently specializes in high-throughput gene expression analysis, targeted gene therapy, immuno and combination therapy for early to late-stage incurable cancers, with an emphasis on patient-derived sample for clinical relevance, advancing cancer diagnosis and therapy.
ICMR-IF.[Visiting Fellow – Stanford University, CA, USA.]
Ph.D. Biochemistry-Biotechnology: Specialization in Cancer Diagnostics, Glycobiology Lab, Medical Biotechnology R & D, Tamil Nad Hospitals (N R I Promoted), Affiliated to University of Madras, Chennai, India.
M.Sc. Biochemistry: Department of Chemistry, Annamalai University, Chidambaram, South India.
B.Sc. Zoology: Chemistry and Botany as Ancillary papers, Gurunanak College, University of Madras, Chennai, India.
Successful synthesis and purification of TAT peptide, conjugated with the tumor-targeting peptide, were achieved to enhance targeted drug delivery. MALDI-TOF analysis confirmed the molecular structure of the conjugate. This novel anticancer peptide, was used for targeted drug delivery.
Bladder cancer is a recurrent disease that often develops chemo-resistance. To facilitate a therapy model, T24 cell line was treated with ‘NXX’ peptide and tested for its cytotoxicity, cell cycle inhibition, etc., in vitro. This peptide based chemotherapy for human bladder cells was found significant that exhibits specific anti-cancer activity on T24 cells in vitro and found to be non-cytotoxic to selected normal cell lines.
Bacteriocins are ribosomally synthesized antimicrobial peptides, that act as defense molecule of the bacteria. They exhibit antagonism against related bacterial species showing its remarkable antiviral effects also. The inhibitory activity of these short peptides against viruses can be exploited as an alternative antiviral therapy against SARS-CoV-2 infection.
Bladder microbiome dysbiosis and altered urinary metabolome are pivotal in Bladder Cancer (BC), yet their association with tobacco remains unclear. The stage and grade of BC for treatment are determined mostly through invasive cystoscopy. Therefore, our study addresses the lacuna, exploring the impact of tobacco on the bladder microbiome and metabolome to deepen understanding of BC pathogenesis.
Young Biomedical Scientist “International Fellowship” was awarded by Indian Council for Medical Research, Ministry of Health & Family Welfare, Government of India., (International to pursue a Fellowship at Stanford University Medical Center, CA, USA. This award by ICMR-DHR is to develop capacity building and human resource development for Biomedical Scientists involved in both basic and clinical sciences.
BRSI, Biotech Research Society is a scientific professional society dedicated to promote excellence and competence in the field of Biotechnology for the benefit of mankind. BRSI helps connect academic institutions with Biotech industries and helps them resolve research problems.
IIS, the Indian Immunology Society is a professional society, to advance the science of Immunology through research and training. The purpose is to use Immunology to fight the major health challenges.
ACBI, Association of Clinical Biochemists of India is an organization that aims to improve the health of communities by advancing the science and practice of Clinical Biochemistry. ACBI publishes journals and news bulletins related to Clinical Biochemistry.
IABMS supports interdisciplinary co-operation amongst Biomedical researchers. IABMS aims, to foster researchers to energize, advance and progress between disciplinary collaboration amongst Biomedical researchers to improve science and innovation.